The drug discovery services company Caliper Life Sciences has struck a deal to acquire Xenogen, which makes imaging systems, for about $80 million. Caliper plans to sell stock and warrants to cover the cost of the buyout.
"This transaction is a transformational event for Caliper," said Kevin Hrusovsky, president and CEO of Caliper. "The acquisitions of Zymark and NovaScreen, organic growth of Caliper's LabChip products and the financial turnaround of our company have set the stage for the merger with Xenogen. We are achieving our goal of building a unique company with first-mover advantage in bridging in vitro and in vivo experimentation."
- read this release for more information